Goodin DS. Disease-modifying therapy in MS: a critical review of the literature. Part II: assessing efficacy and dose-response. J Neuro l 2004;251(Suppl 5):S50-S56.Goodin DS. Disease-modifying therapy in MS: a critical review of the literature. Part I: analysis of clinical trial ...
此外,在风湿病领域的文献中,我们看到这样的英文和译文:Therefore,substantial revenue opportunity for conventional disease-modifying antirheumatic drugs(DMARDs)remains in early lines of therapy[译文:因此,传统的改善疾病的抗风湿药物(DMARDs)的大...
Continuous assessment of infectious risks before, during and after disease-modifying therapy for MS, especially when using intravenous drugs, has increasing clinical relevance Experience with the recently approved oral MS disease-modifying therapies illustrates that even after approval, new treatment-associate...
Zhao GJ, Li DK, Wolinsky JS, et al. Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis. The MS Study Group. J Neuroimaging 1997; 7: 1–7 PubMedCASGoogle Scholar Goodkin DE, Rudick RA, VanderBrag-Medendorp S, ...
Association between disease-modifying therapies for multiple sclerosis and healthcare utilisation on a population level: a retrospective cohort study Disease-modifying therapy (DMT) use in multiple sclerosis (MS) has increased significantly. However, the impact of DMTs on healthcare use is limited and...
disease-modifying therapytreatment starttreatment sequencingtreatment switchsub-optimal treatmentMultiple sclerosis (MS) is a chronic disease whichGrand'MaisonWesternFrancoisWesternYeungWesternMichaelWesternMorrowWesternSarahWesternA.WesternLeeWesternLieslyWestern...
Immunomodulatory therapy of eosinophil-associated gastrointestinal diseases Further understanding of the early events in pathogenesis is also needed to develop preventive and disease-modifying treatments. KD Stone,C Prussin - 《Clinical & Experimental Allergy》 被引量: 119发表: 2010年 An Electrochemical De...
Although currently there is no cure for MS the course of the disease can be influenced by disease modifying therapy (DMT). For therapy to be sufficiently efficient, it is crucial that patients take their medication regularly as prescribed. Adherence describes the extent to which a patient acts ...
Objective: To characterize the initial disease modifying therapy (DMT) and time-to-treatment of people who receive a diagnosis of Multiple Sclerosis (MS).Background: Initiation of DMT expeditiously after diagnosis is important to reduce disease activity and optimize clinical outcome. MS diagnosis can...
Over half of the individuals receiving a DMT for MS in Manitoba remained on therapy for at least 4 years. DMT discontinuation occurred in 60% of the cohort, but most restarted a DMT within 1 year. While not all of the factors identified with discontinuing DMT are modifiable, they may help...